Pharmafile Logo

pegpleranib

- PMLiVE

Novartis’ CAR-T Kymriah scores SMC approval

Will now be available on NHS across the UK

AstraZeneca AZ

Can AZ’s Imfinzi challenge Tecentriq in small cell lung cancer?

New data shows improvement in overall survival

- PMLiVE

Novartis’ lung cancer drug wins FDA Breakthrough Therapy Designation

Provides hope for new treatment of rare cancer

Roche Basel Switzerland

Roche scores EU approval twice for Tecentriq in lung cancer

Carves out space in a market dominated by MSD's Keytruda

- PMLiVE

Genentech agrees trade secret theft settlement with Taiwan’s JHL

Three ex-Genetech workers pleaded not guilty to criminal theft charges

- PMLiVE

NICE backs NHS use of Novartis’ gene therapy Luxturna

First and only therapy for rare, inherited form of blindness

Novartis building

Novartis expands its generics franchise with natalizumab biosimilar

Says affordability is a challenge to access

Roche Basel Switzerland

Roche’s flu drug Xofluza scores phase 3 primary endpoint

Demonstrates efficacy as a preventative treatment

- PMLiVE

Novartis scores promising phase 3 MS study

Takes fight to Roche’s blockbuster ocrevus

- PMLiVE

‘Therapeutic overcrowding’ could hit big pharma returns

Jefferies analysts identify most at-risk companies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links